KYNBKyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting C…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript FG-3246 Phase II trial advances with 36% PSA50 response in monotherapy. | ||
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ... Kyntra Bio Inc (KYNB) reports a net income of $12 million for Q2 2026, driven by key clinical progress in its oncology pipeline and a cash position extending into 2028. | ||
 Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates Kyntra Bio (KYNB) delivered earnings and revenue surprises of -47.17% and -173.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates Kamada (KMDA) delivered earnings and revenue surprises of +33.33% and +6.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates NovoCure (NVCR) delivered earnings and revenue surprises of +56.67% and +5.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||